Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: yosi s who wrote (775)	5/15/1999 9:22:00 AM
From: crysball	Read Replies (1) \| Respond to of 1386

The conference call Well executed, with just the right balance of caution and optimism, to build confidence among those individual and instituinal listeners / contributors to the discussion. Bob Cook hanled the call very professionally. I'm still a skeptic about the performance of B&L sales force in the launch.........There is NO effort focused on the Optometrist (who can prescribe) or the Allergist. While I realize PARS doesn't want to bear the cash drain of their own detailing force, it would seem they could consider: 1) Co-marketing by piggyback ing on the on an existing detailing force reaching Allergists (assumes this is not prhibited by the PARS/B&L agreement) 2)Do a mailing effort targeting Optometrists (or get B&L to do it) 3) Get creative with the worlwide web...........which will soon break down all the classical Distribution Channels.......I'm not suggesting selling Alrex or Lotemax via the web (as are Viagra and certain Diet Pills), but simply starting by creating an end user influence web site which provides information, ssafety profiles etc..........and could even list Physicians who are Lotemx/Alrex prescribers. The web is going to revolutionize marketing and physical distribution channels as we know it today.........it could be an extremely cos-effective tool for leveraging Pharmos........ creating company awarenes, product awareness worldwide..........without having to depend on B&L ......Why not harness the creativity of Omer Shivli in Israel! Ariella, keep up the good work. 3 QUESTIONS 1) the mention about all the samples going out (200,00?)............does PARS receive royalty on samples? 2)(not conference call related) A contributors suggestion the shorts postion will send a message (decline sharply) just prior to HU-211 announcement....may be correct, however, wont the time lag in reporting the short position make ths meaningles? 3) Since my HU-211 announcement projection has passed can I select a new one of August 30?

To: yosi s who wrote (775)	5/17/1999 2:19:00 PM
From: Dr. John M. de Castro	Read Replies (1) \| Respond to of 1386

Lotemax for Arthritis!! John de C Pharmazie 1999 Jan;54(1):58-61 Loteprednol etabonate, a new soft steroid is effective in a rabbit acute experimental model for arthritis. Buris LF, Bodor N, Buris L First Department of Surgery, Medical University of Debrecen, Hungary. Loteprednol etabonate, a new soft steroid designed for use as a local therapeutic, was compared to dexamethasone in rabbit experimental model for arthritis. METHODS: Joint inflammation was induced by local injection of antigen into the patellofemoral articulation in sensitized rabbits. Co-administration of either dexamethasone or loteprednol etabonate directly into the joint effectively blocked the inflammatory response. Both the synovial fluid cellular content and synovium histology were examined. The steroid treatments prevented the adverse inflammatory effects of antigen action. These results, together with previous studies showing decreased systemic activity of the soft steroid, indicate that the loteprednol etabonate could provide a therapeutic advantage over currently used intra-articular steroids for alleviating rheumatoid arthritis.